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Expression or release of immunosuppressive molecules may protect tumor cells from the recognition and destruction by
the immune system. New findings indicate that colorectal tumors produce immunoregulatory glucocorticoids and
thereby suppress immune cell activation. The nuclear receptor LRH-1 plays a critical role in the regulation of colorectal
tumor proliferation and glucocorticoid synthesis.
Immune responses against tumors and
their role in the control of tumor develop-
ment are a complex and in many aspects a
rather controversial issue. While there is
strong evidence from a variety of experi-
mental systems as well as clinical studies
with tumor patients that immune cells and
their effector functions may limit tumor
growth, other data indicate that immune
cell-derived factors and associated inflam-
mation rather enhance tumor cell survival
and growth. Thus, the role of anti-tumor
immune responses in the control of tumor
development is not yet universally solved.
Yet, if anti-tumor immune responses are
indeed able to limit or suppress tumor
development, the prediction can be made
that immunosuppressive factors released
by tumor cells will likely enhance tumor
survival and growth. In line with this
notion are recent tumor patient-based
studies on the correlation between patient
survival and tumor infiltration by immune
cells, demonstrating that high levels of
memory T cells are a good and positive
prognostic factor for the overall patient’s
survival (reviewed in ref. 1). While these
data convincingly demonstrate that pres-
ence or absence of anti-tumor immune
responses determines the patient’s fate, it is
presently unclear how tumor cells prevent
immune cell infiltration and thereby can
evade host defense mechanisms.
In a recent study published in Oncogene
2
we now show that colorectal tumors are a
rich source of immunoregulatory gluco-
corticoids and propose that tumor-derived
glucocorticoids may contribute to immune
evasionbyinhibitingimmunecellactivation
and promoting apoptosis. Glucocorticoids
are steroid hormones with important anti-
inflammatory and pro-apoptotic properties.
Though the adrenal glands are the most
prominent source of glucocorticoids, alter-
native sources have been demonstrated,
including thymus, skin, intestine and the
lung.
3,4 Our own studies identified the
proliferating cells of the intestinal crypts as
the major source of intestinal glucocorti-
coids in response to immunological stress.
5
Intestinal glucocorticoids critically contri-
bute to the maintenance of immune
homeostasis in the intestinal mucosa, as
evidenced by an increased susceptibility to
the development of intestinal inflammation
in the absence of intestinal glucocorticoid
synthesis.
6,7 Colorectal tumor cells, derived
from these intestinal crypt cells, have
maintained the potential to produce gluco-
corticoids, employing the same signal trans-
duction pathways and enzymatic cascades.
In contrast to primary epithelial cells
glucocorticoid synthesis in tumor cells is
constitutively induced. Although steroid
production has been previously described
in tumors derived from primary steroido-
genic organs, such as adrenals, testis and
ovaries, this study demonstrates for the first
time the synthesis of glucocorticoids by a
tumor derived from a non-endocrine tissue.
Of particular interest in this regard is
the role of the nuclear receptor and trans-
cription factor liver receptor homolog-1
(LRH-1, NR5a2). LRH-1 is a transcrip-
tion factor with an increasingly recognized
role in metabolism, cell cycle regulation
and steroid synthesis (reviewed in ref. 8).
In the intestine LRH-1 critically regulates
immune cell-induced glucocorticoid syn-
thesis via the induction of steroidogenic
enzymes,
9 and consequently LRH-1-
deficient mice are more susceptible to the
development of experimental colitis.
7 As
in primary intestinal crypt cells, LRH-1 is
also a critical regulator of glucocorticoid
synthesis in colorectal tumor cells. Not
surprisingly, while in primary epithelial
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cells LRH-1 expression is restricted to the
proliferating cells of the crypts, LRH-1
is massively overexpressed in colorectal
tumor cells.
2 Likely, LRH-1 has a dual role
in the development of colorectal tumors.
While the induction of glucocorticoid
synthesis may promote suppression of
tumor-infiltrating immune cells and
evasion from destruction by cytotoxic
effector mechanisms, LRH-1 also directly
promotes tumor cell proliferation via the
induction of cyclin D1 and E1 (Fig.1).
Along these lines it was shown that LRH-1
promotes adenoma development in the
APC
min/+ mouse model for intestinal
tumor formation.
8
Signals leading to LRH-1 activation
are thus most interesting targets for the
treatment of colorectal tumors by simulta-
neously targeting proliferation and gluco-
corticoid synthesis. Interestingly, signaling
pathways regulating the proliferation in
primary and tumor cells, such as the EGF
receptor signaling pathway, have also been
shown to promote LRH-1 activation.
10
Surprisingly, even TNFa, a cytokine
well know for its pro-inflammatory
and immunostimulatory properties, was
recently identified by us as a key regulator
of intestinal glucocorticoid synthesis,
6 and
could thus also likely promote glucocorti-
coid synthesis in colorectal tumor cells
(Fig.1). Future studies specifically target-
ing the glucocorticoid synthesis in tumor
cells, e.g., by LRH-1 antagonists or inhi-
bitors of steroidogenic enzymes, have to
further evaluate the importance of extra-
adrenal glucocorticoid synthesis in the
development of colorectal cancer.
In summary, our present study descri-
bes for the first time glucocorticoid syn-
thesis in tumor cells from non-endocrine
tissue and its regulatory activities on
immune cells. As we recently also identi-
fied the lung mucosa as a rich source of
glucocorticoids,
4 suggesting that also lung
cancer cells may be able to produce
glucocorticoids, it is very likely that
glucocorticoid synthesis by tumor cells is
a more general mechanism of immune
evasion by epithelial tumors.
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Figure1. Proposed role of LRH-1 and glucocorticoid synthesis in tumor immune evasion.
Tumor-infiltrating immune cells, such as T cells, macrophages (MW) and dendritic cells (DC),
release factors, such as TNFa, which stimulate the activation of the transcription factor LRH-1
in colorectal tumor cells. LRH-1 regulates the transcription of cyclins, leading to tumor cell
proliferation, and steroidogenic enzymes (cytochrome P450 enzymes, Cyp), leading to the synthesis
of glucocorticoids (GC). Glucocorticoids in turn suppress the activation of cytotoxic T cells and
innate immune cells. LRH-1 can also be activated via the MAP kinase (MAPK) pathway upon
stimulation of growth factor receptors, such as the epidermal growth factor (EGF) receptor.
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